PRZOOM - /newswire/ -
Mountain View, CA, United States, 2011/03/23 - As the preimplantation genetic diagnosis (PGD) market is at a very early stage, the virtually untapped market harbors several targets for strategic acquisition.
This market also offers new applications for advanced genomic technologies like Array CGH.
New analysis from Frost & Sullivan (drugdiscovery.frost.com), U.S. Preimplantation Genetic Diagnosis Market, finds that the market earned revenues of $23.1 million in 2010 and estimates this to reach $33 million in 2017.
If you are interested in more information on this study, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.
Assisted Reproductive Technology (ART) procedures and associated services, such as genetic testing of embryos produced from an ART cycle, will be in high demand as the number of women delaying motherhood is increasing. Couples that use in vitro fertilization (IVF) to become pregnant have a unique opportunity to assess aneuploidy or genetic mutations before embryos are implanted.
The ability to screen or diagnose genetic abnormalities as early as possible is pertinent to couples that have experienced recurring pregnancy loss by aneuploidy and are seeking treatment with ART. PGD screening of embryos for aneuploidy will be a major growth area as approximately half of the cases of embryonic loss within ART are associated with aneuploidy.
PGD is effective in detecting chromosomal and single-gene disorders with more than 99 percent diagnostic accuracy. The highly reliable test results are likely to drive an infertility medical professional or PGD genetic counselor to recommend the procedure.
"The success of ongoing clinical trials for broadening the scope of PGD testing of embryos beyond high-risk indications will go a long way in developing the market," said Frost & Sullivan industry analyst Winny Tan. "Without an indication that broadly reinforces the benefit from PGD, the market will remain a niche one."
Patient access to PGD will be limited until more PGD services experience reimbursement. The dynamics of the infertility markets and the high costs of IVF ultimately dictate the PGD market's characteristics. A reduction in IVF cycles can dampen the PGD market. However, greater market saturation achieved by expanding PGD services will promote overall growth in the future.
The current low market saturation indicates just how important effective customer marketing is. PGD market participants can compete more aggressively by targeting all customer segments of IVF, including key groups like infertility clinics and infertility patients.
"PGD labs should work closely with the medical staff at the IVF clinics that they serve," said Tan. "This trained staff of infertility experts, reproductive health physicians and PGD genetic counselors interface directly with IVF patients and are in the best position to advise or endorse PGD testing."
U.S. Preimplantation Genetic Diagnosis Market is part of the Clinical Diagnostics Growth Partnership Services program, which also includes research in the following markets: U.S. Inherited Disease Molecular Diagnostics Market, European Market for Foetal and Neonatal Monitoring Equipment Market, Advances in Fetal and Neonatal Diagnostics and Monitoring and U.S. Genetic Diagnostics Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.
U.S. Preimplantation Genetic Diagnosis Market / N8A4